Capricor Therapeutics’ (CAPR) Hold Rating Reaffirmed at JonesTrading

JonesTrading reaffirmed their hold rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a report issued on Friday morning,Benzinga reports.

Several other equities analysts have also recently issued reports on CAPR. B. Riley Financial cut Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $10.00 price objective on the stock. in a research note on Monday, July 27th. Maxim Group lowered shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday. Piper Sandler cut shares of Capricor Therapeutics from an “overweight” rating to a “neutral” rating and set a $2.00 target price on the stock. in a report on Thursday. Alliance Global Partners downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price target on the stock. in a research report on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Monday, June 15th. Ten equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Capricor Therapeutics currently has a consensus rating of “Reduce” and a consensus price target of $29.15.

Capricor Therapeutics Stock Down 8.1%

Shares of NASDAQ CAPR opened at $3.85 on Friday. The stock’s 50 day moving average price is $23.00 and its two-hundred day moving average price is $26.77. Capricor Therapeutics has a 52-week low of $2.96 and a 52-week high of $40.37. The stock has a market capitalization of $222.95 million, a P/E ratio of -1.66 and a beta of 0.42.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). On average, analysts anticipate that Capricor Therapeutics will post -0.84 EPS for the current year.

Insider Buying and Selling at Capricor Therapeutics

In related news, CFO Anthony Bergmann sold 24,100 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $30.38, for a total value of $732,158.00. Following the sale, the chief financial officer owned 11,223 shares of the company’s stock, valued at approximately $340,954.74. This trade represents a 68.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders sold 25,000 shares of company stock worth $759,158. 9.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. increased its position in Capricor Therapeutics by 122.2% in the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock worth $37,000 after buying an additional 2,786 shares during the period. ACT Capital Management LLC acquired a new position in shares of Capricor Therapeutics during the fourth quarter valued at $43,000. KBC Group NV acquired a new position in shares of Capricor Therapeutics during the first quarter valued at $44,000. Tower Research Capital LLC TRC boosted its holdings in shares of Capricor Therapeutics by 280.8% during the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after acquiring an additional 4,976 shares during the period. Finally, Regal Investment Advisors LLC bought a new position in shares of Capricor Therapeutics during the third quarter worth about $92,000. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics News Summary

Here are the key news stories impacting Capricor Therapeutics this week:

• Neutral Sentiment: The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee voted 9-3 that available evidence did not support Deramiocel’s effectiveness. The vote is non-binding, so the FDA could still reach a different decision, but it is a significant setback for Capricor’s regulatory path. Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
• Neutral Sentiment: FDA briefing materials and media reports questioned whether Deramiocel met its pre-specified cardiac endpoint and challenged Capricor’s interpretation of Phase 3 results. The dispute centers on changes to the statistical analysis plan that allegedly were not agreed to by the FDA before the company resubmitted its biologics license application. Capricor plummets after FDA panel votes against Duchenne heart disease therapy
• Negative Sentiment: Multiple law firms have announced securities-fraud investigations or filed shareholder class actions alleging that Capricor made materially misleading statements or failed to disclose regulatory and clinical-data risks related to Deramiocel. The lawsuits add legal, financial and reputational risk, although the allegations have not been proven. Investors have been encouraged to contact the firms, with some notices citing a September 28, 2026 deadline. CAPR Investor Alert: Class Action Lawsuit Filed on Behalf of Capricor Therapeutics Investors
• Negative Sentiment: Analysts responded by cutting ratings, including downgrades from Cantor Fitzgerald, Maxim Group, Ladenburg Thalmann and Alliance Global Partners. Cantor moved to Neutral with a $3.50 price target, while JonesTrading reaffirmed a Hold rating. Capricor Therapeutics downgraded by Cantor Fitzgerald

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.